Cargando…

Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro

Detalles Bibliográficos
Autores principales:	Yamada, Reiko, Steward, Kristopher, Ngarmchamnanrith, Gataree, Trinh, Ryan, Khare, Sanjay, Sachdev, Raj, Grewal, Iqbal, Morrison, Sherie, Timmerman, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991073/ http://dx.doi.org/10.1186/2051-1426-1-S1-P263

Ejemplares similares

IGN004 is an antibody-interferon-alpha fusion protein against a novel tumor-associated antigen with both direct anti-tumor and immunostimulatory effects
por: Steward, Kristopher K, et al.
Publicado: (2015)

Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro
por: Amouzadeh, Hamid R., et al.
Publicado: (2019)

Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
por: Wen, Jing, et al.
Publicado: (2021)

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
por: Tran, Ben, et al.
Publicado: (2018)

Correction: Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
Publicado: (2021)

Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy
por: VEGA, GABRIEL G., et al.
Publicado: (2015)

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
por: Hörl, S, et al.
Publicado: (2013)

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
por: Hörl, S, et al.
Publicado: (2013)

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
por: Dwojak, M, et al.
Publicado: (2015)

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
por: Felberg, Anna, et al.
Publicado: (2020)

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
por: Hong, David S., et al.
Publicado: (2015)

Complement Has Brains—Do Intracellular Complement and Immunometabolism Cooperate in Tissue Homeostasis and Behavior?
por: Kunz, Natalia, et al.
Publicado: (2021)

Denitrification in foraminifera has an ancient origin and is complemented by associated bacteria
por: Woehle, Christian, et al.
Publicado: (2022)

RELAPSE AND REMITTING COVID-19 INFECTIONS IN AN IMMUNOSUPPRESSED PATIENT ON CHRONIC RITUXIMAB INFUSIONS
por: GREWAL, SAHIB, et al.
Publicado: (2021)

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

Coordinated local RNA overexpression of complement induced by interferon gamma in myositis
por: Casal-Dominguez, Maria, et al.
Publicado: (2023)

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
por: Raterman, Hennie G, et al.
Publicado: (2012)

Thrombotic Thrombocytopenic Purpura in a Patient with Interferon Treated Hepatitis C Successfully Treated with Rituximab
por: Poddar, Nishant, et al.
Publicado: (2013)

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab
por: de Jong, Tamarah D, et al.
Publicado: (2015)

A Rapid and Economic In-House DNA Purification Method Using Glass Syringe Filters
por: Kim, Yun-Cheol, et al.
Publicado: (2009)

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
por: Malenge, Marion M., et al.
Publicado: (2020)

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy
por: Bordron, Anne, et al.
Publicado: (2018)

Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis
por: Ge, Xiaowen, et al.
Publicado: (2021)

Bispecific mAb(2) Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab
por: Stadlbauer, Katharina, et al.
Publicado: (2022)

Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma
por: Lara, Sandra, et al.
Publicado: (2022)

Complement and viral pathogenesis
por: Stoermer, Kristina A., et al.
Publicado: (2011)

Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis
por: Schmidt, Brian J, et al.
Publicado: (2013)

Anthropogenic climate change has altered primary productivity in Lake Superior
por: O'Beirne, M. D., et al.
Publicado: (2017)

Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells
por: Li, Yang, et al.
Publicado: (2019)

Rituximab
por: Tridente, Giuseppe
Publicado: (2013)

Inhibitors of MyD88-Dependent Proinflammatory Cytokine Production Identified Utilizing a Novel RNA Interference Screening Approach
por: Cho, John S., et al.
Publicado: (2009)

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
por: Reddy, Venkat, et al.
Publicado: (2017)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Complement Potentiates Immune Sensing of HIV-1 and Early Type I Interferon Responses
por: Posch, Wilfried, et al.
Publicado: (2021)

Genetic Variability of Complement Factor H Has Ethnicity-Specific Associations With Choroidal Thickness
por: Fenner, Beau J., et al.
Publicado: (2023)

Agastache honey has superior antifungal activity in comparison with important commercial honeys
por: Anand, Sushil, et al.
Publicado: (2019)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Recombinant IgA Antibodies
por: Yoo, Esther M., et al.
Publicado: (2007)

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
por: Chu, Te-Wei, et al.
Publicado: (2015)

Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?
por: Raj, Naveen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_riov63gb36c14j29mrd9l2hi5p